膀胱癌的分子病理学
本文综述膀胱癌的分子病理学进展,涵盖分子分型、生物标志物及个性化治疗。从染色质修饰基因突变到关键驱动基因改变,强调从形态学分类向形态与分子结合分类的转变,并讨论FGFR3、Nectin-4、Trop-2及HER2等靶点的治疗意义。
要点
- 染色质修饰基因KMT2D和KDM6A突变促进尿路上皮广泛定植。
- TP53、PIK3CA、FGFR3或RB1突变驱动恶性转化。
- FGFR3改变常见于管腔乳头亚型且免疫治疗反应低,erdafitinib靶向此改变。
核心结论
- 膀胱癌分子病理学进展显著,分子分型与生物标志物指导的个性化治疗正在改变局部晚期和转移性疾病的管理。
研究设计与样本
- 本文为综合性综述,总结膀胱癌分子病理学、分子分型、生物标志物及个性化治疗进展。
主要发现
- 染色质修饰基因KMT2D和KDM6A突变促进尿路上皮较大区域定植,随后TP53、PIK3CA、FGFR3或RB1突变驱动恶性转化。
- FGFR3改变常见于管腔乳头分子亚型,该亚型免疫治疗反应低,FGFR3是erdafitinib的靶点。
- Nectin-4在>95%的尿路上皮癌中表达,enfortumab vedotin靶向Nectin-4,已获批用于化疗和/或免疫治疗后进展的患者。
- Nectin-4基因扩增可能进一步细化患者分层。
- Sacituzumab govitecan靶向Trop-2,在基底、管腔和富间质亚型中有效,但在神经内分泌癌中无效。
关键数值与推荐
- FDA批准trastuzumab deruxtecan用于HER2过表达转移性尿路上皮癌,基于DESTINY泛肿瘤II期试验数据。
- Enfortumab vedotin靶向Nectin-4,适用于化疗和/或免疫治疗后进展的患者。
- Sacituzumab govitecan在基底、管腔和富间质亚型中有效,神经内分泌癌无效。
临床怎么用
- 膀胱癌管理应整合临床、病理和分子分类,指导局部晚期和转移性疾病的治疗决策。
- FGFR3改变提示管腔乳头亚型且免疫治疗反应低,可考虑erdafitinib靶向治疗。
- Nectin-4表达和基因扩增状态可用于enfortumab vedotin治疗的患者分层。
- HER2过表达转移性尿路上皮癌可使用trastuzumab deruxtecan。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Significant progress has been achieved in elucidating the molecular underpinnings of bladder cancer initiation and progression. Translational research has identified mutations in chromatin-modifying genes such as KMT2D and KDM6A, which facilitate colonization of larger regions of the urothelium. Subsequent mutations in TP53, PIK3CA, FGFR3 or RB1 drive malignant transformation. Advances in personalized oncology now integrate clinical, pathological and molecular classifications in bladder cancer, representing a paradigm shift in the management of locally advanced and metastatic disease. Alterations in FGFR3, commonly found in the luminal-papillary molecular subtype associated with low response to immunotherapy, are the target of erdafitinib. Enfortumab vedotin, which targets Nectin-4 (expressed in >95% of urothelial carcinomas), is approved for patients who progress after chemotherapy and/or immunotherapy. Evidence suggests that Nectin-4 gene amplification may further refine patient stratification. Sacituzumab govitecan, an antibody-drug conjugate directed against Trop-2, is effective in basal, luminal and stroma-rich subtypes but not in neuroendocrine carcinomas. In addition, therapies developed for HER2-positive breast cancer have shown efficacy in urothelial carcinoma, with recent data from the DESTINY pan-tumour phase II trial leading to FDA approval of trastuzumab deruxtecan for HER2-overexpressing metastatic urothelial carcinoma. This paper is a comprehensive review of the molecular pathology of bladder cancer, highlighting advances in molecular classification, biomarkers and personalized therapies. The transition from morphology-based classifications to combined morphological and molecular approaches, with therapeutic implications, is also addressed.
引用
- Lopez-Beltran A, Blanca A, Downes MR, et al. Molecular pathology of bladder cancer. Histopathology. 2026. PMID: 41384708. doi:10.1111/his.15555
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。